Cargando…
OX40 Agonists and Combination Immunotherapy: Putting the Pedal to the Metal
Recent studies have highlighted the therapeutic efficacy of immunotherapy, a class of cancer treatments that utilize the patient’s own immune system to destroy cancerous cells. Within a tumor the presence of a family of negative regulatory molecules, collectively known as “checkpoint inhibitors,” ca...
Autores principales: | Linch, Stefanie N., McNamara, Michael J., Redmond, William L. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4329814/ https://www.ncbi.nlm.nih.gov/pubmed/25763356 http://dx.doi.org/10.3389/fonc.2015.00034 |
Ejemplares similares
-
Combination OX40 agonism/CTLA-4 blockade with HER2 vaccination reverses T cell anergy and promotes survival in tumor-bearing mice
por: Linch, Stefanie, et al.
Publicado: (2015) -
Combined OX40 ligation plus CTLA-4 blockade: More than the sum of its parts
por: Linch, Stefanie N, et al.
Publicado: (2014) -
Combination OX40 agonism/CTLA-4 blockade with vaccination reverses anergy and primes tumor-specific CD8 T cells in mice with spontaneous prostate cancer
por: Linch, Stefanie N, et al.
Publicado: (2013) -
Combined targeting of co-stimulatory (OX40) and co-inhibitory (CTLA-4) pathways elicits potent effector T cells capable of driving robust anti-tumor immunity
por: Redmond, William L, et al.
Publicado: (2013) -
Development of OX40 agonists for canine cancer immunotherapy
por: Ruiz, Damien, et al.
Publicado: (2022)